Catheter ablation and functional status in HFpEF

Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) commonly coexist, especially in older adults. Together they can cause disproportionate breathlessness, fatigue, reduced exercise capacity, and recurrent hospital admissions despite a structurally normal-looking left ventricle. Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Impact on Functional Status asks whether restoring sinus rhythm improves everyday function, rather than merely reducing documented AF episodes.

HFpEF is not simply a high ejection fraction. It reflects impaired filling and elevated intracardiac pressures arising from hypertension, obesity, diabetes, kidney disease, valvular disease, or other factors. AF adds irregular ventricular activation, variable diastolic filling, reduced exercise cardiac output, and sometimes tachycardia-related myocardial injury. These mechanisms make symptom burden and functional capacity meaningful endpoints when evaluating rhythm control.

Restoring sinus rhythm may remove an aggravating arrhythmia, but it cannot reverse every component of HFpEF. The strongest rationale is a treatable AF burden demonstrably contributing to limitation. Trials and observational series suggest that catheter ablation can improve symptoms, walking distance, and quality of life in selected people with HFpEF, yet evidence for preventing death or long-term readmission remains limited and sensitive to selection, procedural success, and follow-up.

For Australian patients, gains can be substantial: walking to a tram stop, climbing home stairs, cycling along the foreshore, or managing a work shift may matter more than a small change in a laboratory value. Geography, public-hospital waiting times, out-of-pocket costs, and access to specialist follow-up also determine whether a technically successful procedure becomes a durable health benefit.

Why functional status matters in HFpEF

Functional status should be measured before and after ablation with more than symptoms alone. Useful assessments include the 6-minute walk test, cardiopulmonary exercise testing, peak oxygen uptake, NYHA class, and validated patient-reported tools such as the Kansas City Cardiomyopathy Questionnaire or EQ-5D. Serial blood pressure, weight, congestion, natriuretic peptides, sleep apnoea, and medication changes help separate rhythm effects from changes in HFpEF care.

AF symptoms vary, and some recurrences are silent. A patient may remain breathless despite fewer AF episodes because obesity, pulmonary hypertension, coronary disease, or deconditioning dominates. A meaningful outcome combines objective exercise gain, symptom relief, fewer HF admissions, and a return to valued activities; sinus rhythm at a single clinic visit cannot establish it.

Selecting patients for likely benefit

Ablation is most plausible when symptomatic paroxysmal or persistent AF limits daily activity and rate or medical rhythm control has not met the patient’s goals. Rhythm history, AF burden, ventricular rates, blood pressure, left atrial size, pulmonary pressures, and a direct account of when symptoms occur help identify an arrhythmic contribution.

Potential high responders include people with marked exertional limitation during AF, recurrent HF admissions with a high AF burden, or early HFpEF in whom rapid or irregular conduction adds to impaired filling. Response is less predictable when symptoms are trivial, AF burden is minimal, or advanced pulmonary vascular disease and frailty dominates. Age alone should not exclude treatment, but procedural risk, life expectancy, anticoagulation needs, and patient priorities must be considered together.

Assessment should address reversible contributors such as hypertension, obesity, sleep apnoea, diabetes, iron deficiency, alcohol, and medication toxicity. In younger patients with unexplained syncope, ventricular arrhythmia, or a family history of sudden cardiac death, the team should distinguish an inherited channel disorder from AF/HFpEF itself. A review of long-QT genotype–phenotype correlations shows why genetic findings require phenotypic context and specialist interpretation.

What the evidence shows

The randomised AATAC-HFpEF trial enrolled 210 patients and compared ablation with medical therapy. At 12 months, the ablation group had greater freedom from AF, roughly 40 m more improvement in 6-minute walk distance, better HF symptoms, and a small increase in ejection fraction; HF-related events were also fewer in this small sample. The results support functional benefit, but limited events and follow-up prevent firm mortality claims.

Systematic reviews generally report improvements in exercise capacity, symptom scores, diastolic measures, and sometimes EF, but studies are often small, single-centre, and heterogeneous in AF definitions, ablation lesions, imaging, and outcome thresholds. Landmark trials such as CABANA and EAST-AFNET 4 included people with heart failure, but their HFpEF evidence was not designed to settle functional recovery and hospital prevention.

Statistics require clinical context. A 6-minute walk change must exceed expected variability and matter to the patient, while questionnaires should show meaningful rather than merely statistical shifts. It remains unclear whether functional improvement predicts fewer long-term HF admissions, or whether the restored atrial contribution to ventricular filling helps different HFpEF phenotypes equally. These uncertainties support shared decisions and structured follow-up.

Ablation strategy and follow-up

Most procedures use pulmonary vein isolation, often with additional lesions directed at triggered activity or atrial substrate. The target is durable pulmonary vein isolation while balancing radiation, procedure time, and risks including vascular injury, phrenic nerve dysfunction, oesophageal injury, pulmonary vein stenosis, and thromboembolism. Electroanatomical mapping, intracardiac echocardiography, and CT or MRI assessment can support procedure planning, although anatomy and local expertise remain important.

Anticoagulation requires a plan based on stroke and bleeding risk, ablation strategy, and interruption protocols; it cannot be stopped simply because ablation is planned or symptoms improve. Decisions about direct oral anticoagulants, interruption, and heparin bridging should follow current guidance and individual circumstances. Long-term anticoagulation after ablation is generally guided by stroke-risk scores rather than procedural success alone.

Follow-up should extend beyond the three-month blanking period because asymptomatic recurrence can delay benefit. Rhythm monitoring, symptom diaries, repeat walking tests, medication review, and adjustment of congestion-directed therapy help identify response or recurrence. Pulmonary rehabilitation, resistance training, nutrition support, sleep-apnoea treatment, and social prescribing may magnify rhythm-control benefits when obesity or deconditioning drives HFpEF.

Applying the evidence in Australia

Australian pathways combine general practice, cardiology, public electrophysiology services, and private catheter laboratories. Medicare rebates support specialist consultations, while public waiting lists and private gaps affect selection and timing. Capacity for echocardiography, advanced mapping, and post-ablation monitoring varies across Sydney, Melbourne, Brisbane, and regional centres. Telehealth can support rural follow-up, but it cannot replace urgent assessment, medication access, or in-person review when needed.

Everyday activity makes functional outcomes especially relevant in Australia. Sunrise walks, coastal cycling, dog walking, gardening, and standing for work shifts can reveal gains invisible to a resting heart rate. Aboriginal and Torres Strait Islander patients and people in remote communities face barriers tied to distance, workforce distribution, housing, and historical inequity. Culturally safe care, Aboriginal Medical Services, coordinated transport, and local ECG access should be included in access planning.

Costs and regulation shape the Australian market. The Therapeutic Goods Administration assesses marketed ablation devices, generators, and catheters before lawful supply, while Pharmaceutical Benefits Scheme-listed anticoagulants influence affordability; rapid technology uptake is not automatic. Quality registries and remote monitoring may hold identifiable health information, so consent, data security, the Privacy Act 1988, and applicable state or territory health-records laws matter. Clinicians and trainees can consult Journal of Arrhythmia’s scope and access information for open-access research and education.

Patients with AF and HFpEF should raise breathlessness and exercise limitation as treatment goals rather than accept rhythm control as the only measure. Clinicians should document baseline function, refer suitable cases to an experienced AF/HFpEF electrophysiology service, and reassess rhythm and functional outcomes together. Judge the result by what patients can do after the procedure.